Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prolact HM is a pasteurized human milk product manufactured by Prolacta Bioscience. It is intended for use as a nutritional source when mother’s own milk is unavailable, particularly in neonatal intensive care settings. The product consists of 100% donor human milk that has been screened for drugs and infectious agents, then pasteurized to reduce pathogenic viruses (such as HIV, HBV, HCV) and bacteria (including E. coli, S. aureus, Klebsiella species). Prolact HM provides at least 67 kcal per 100 mL but contains no added minerals or fortifiers; it is nutritionally incomplete and may require supplementation with vitamins and iron depending on the infant's needs. The primary indication is for feeding premature or critically ill infants who cannot receive their mother's own breast milk[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prolact HM.